Using novel cultivating methods, scientists can directly induce stem cells to form 3D structures, called organoids, that resemble tissues or organs in the body.
Accurate International (Chinese：创芯国际) announced the completion of a pre-Series B financing round worth CNY 100 million on October 28. This funding round was led by Fortune Capital (Chinese：达晨财智), followed by Guangzhou Jinkong Fund (Chinese：广州金控), GDD Industry Fund Investment Group (Chinese：广州开发区基金), Wanlian Securities (Chinese：万联证券) and Zhonghe Anke Biomedical Industry Fund (Chinese：中合安科). Funway Capital (Chinese：趣道资产), which previously invested in the company's Series A financing round in March 2021, also participated in this round.
Accurate International will continue to increase investment in the R&D of core technologies and products to build a comprehensive organoid life-cycle technology platform.
Founded in 2018, Accurate International is an innovative biomedical enterprise focused on organoid technologies. The company is committed to personalized treatment, new drug R&D and regenerative medicine.
Based on a 3D in vitro cell culture system, organoids are highly similar to source tissues or organs in vivo. Compared to the conventional 2D cell culture models, organoids contain a wide variety of cell types, enabling more efficient and practical drug efficacy and toxicity detection. As a result, organoid technology has broad prospects for applications in fundamental research, clinical diagnosis and treatment.
The founding of Chinese organoid companies was concentrated between 2018 to 2021. Relevant enterprises include Daxiang Biotech (Chinese：大橡科技), K2 Oncology (Chinese：科途医学) and Avatarget (Chinese：艾玮得生物).